Synapse Open Synapse
Biology

Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilience

BioPharma Dive · · 5 min read

AstraZeneca will “redeploy resources” through a new restructuring program. Meanwhile, Alnylam shares sold off on fears surrounding a top drug and investors rewarded Regeneron for a record quarter.

Latest from BioPharma Dive